Core Viewpoint - Zhonghui Biotech-B (02627) saw a stock increase of over 5%, currently trading at HKD 42.68 with a transaction volume of HKD 8.3148 million, following the announcement of the initiation of Phase I clinical trials for its quadrivalent and trivalent influenza virus subunit vaccines [1] Group 1: Clinical Trials and Approvals - The company has recently launched Phase I clinical trials for its quadrivalent influenza virus subunit vaccine (adjuvanted) and trivalent influenza virus subunit vaccine (adjuvanted) [1] - The quadrivalent influenza virus subunit vaccine (adjuvanted) received approval from the National Medical Products Administration of the People's Republic of China for clinical trial application in July 2024, while the trivalent version is set for approval in October 2024 [1] Group 2: Target Demographic and Vaccine Design - The vaccines are specifically designed for individuals aged 65 and above, as this demographic experiences a natural decline in immune function with age, making them more susceptible to severe illness and death from influenza [1] - The inclusion of the MF59-like adjuvant enhances immune response and increases antibody titers, providing better protection for the elderly population [1]
中慧生物-B涨超5% 三价、四价流感病毒亚单位疫苗进入Ⅰ期临床试验阶段